Featured Research

from universities, journals, and other organizations

Long-term elder care patients and HIV infected patients may carry MRSA in their noses

Date:
April 24, 2010
Source:
Lifespan
Summary:
Researchers have determined that long-term elder care, HIV-infected and hemodialysis patients are at increased risk of carrying MRSA in their nose. The study also found that patients have vastly different quantities of MRSA in their noses, a potential indicator for their risk of developing an infection after surgery.

A multi-center study led by a researcher at Rhode Island Hospital has determined that long-term elder care, HIV-infected and hemodialysis patients are at increased risk of carrying methicillin-resistant Staphylococcus aureus (MRSA) in their nose. The study also found that patients have vastly different quantities of MRSA in their noses, a potential indicator for their risk of developing an infection after surgery. The study appears in the June 2010 edition of the journal Infection Control and Hospital Epidemiology and appears online in advance of print.

In order to better understand the prevalence of MRSA in different patient populations, lead author Leonard Mermel, DO, ScM, worked with researchers at The Cleveland Clinic, Johns Hopkins Medical Institutions, Emory University and other organizations to obtain specimens from the noses of a variety of patients. Mermel is the medical director, department of epidemiology & infection control at Rhode Island Hospital.

In general, one in three individuals is colonized with Staphylococcus aureus, most often involving the nose. In the US, approximately 1 percent of people carry MRSA in their nose. Carrying MRSA in the nose increases the risk of developing an invasive MRSA infection such as bloodstream infection, pneumonia, surgical site infection, etc.

Staphylococcus aureus is the second most common pathogen causing health care-associated infections in the United States, and 49 percent of those infections are caused by the highly antibiotic-resistant bacteria MRSA. A strain called USA100 is the most common type of MRSA involved in health care-associated infections in U.S. hospitals.

In this study, 444 nose cultures of 2,055 patients from 13 enrollment centers resulted in growth of MRSA. The researchers found that 14 percent and 15 percent of inpatient and outpatient hemodialysis patients, respectively, carried nasal MRSA, as did 16% of HIV infected patients, and 20 percent of long-term elder care residents. Based on these findings, Mermel, who is also a professor of medicine at The Warren Alpert Medical School of Brown University and a physician with University Medicine, recommends, "Hospitals performing active surveillance for MRSA should consider such patient populations for screening cultures."

The researchers also found different strains of MRSA in different patient populations. For example, while USA100 was the most common MRSA strain detected, the USA 300 strain was much more commonly found in HIV-infected patients. The researchers also detected some MRSA strains not previously identified in the US, such as an MRSA clone common in Brazil.

Mermel and his colleagues also found dramatic diversity in the quantity of MRSA colonizing the noses of people. Some people had as few as 3 colonies of MRSA in their nose detected with a nasal swab whereas others had as many as 15 million colonies of MRSA. Mermel notes, "This finding is important because heavy MRSA colonization of the nose is an independent risk factor for the development of a surgical site infection."

Mermel says the study findings identify patient populations at increased risk for MRSA carriage and infection. Future studies can use this information to determine a biologic explanation for differences in strains and quantities of MRSA that some people carry in their noses.


Story Source:

The above story is based on materials provided by Lifespan. Note: Materials may be edited for content and length.


Journal Reference:

  1. Freitas et al. Prevalence of USA300 Strain Type of Methicillin‐Resistant Staphylococcus aureus among Patients with Nasal Colonization Identified with Active Surveillance. Infection Control and Hospital Epidemiology, 2010; 31 (5): 469 DOI: 10.1086/651672

Cite This Page:

Lifespan. "Long-term elder care patients and HIV infected patients may carry MRSA in their noses." ScienceDaily. ScienceDaily, 24 April 2010. <www.sciencedaily.com/releases/2010/04/100420114229.htm>.
Lifespan. (2010, April 24). Long-term elder care patients and HIV infected patients may carry MRSA in their noses. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/04/100420114229.htm
Lifespan. "Long-term elder care patients and HIV infected patients may carry MRSA in their noses." ScienceDaily. www.sciencedaily.com/releases/2010/04/100420114229.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins